Drug · CHEMBL41
FLUOXETINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. FLUOXETINE. Drugs and targets, record CHEMBL41. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL41
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SLC6A4 | Sodium-dependent serotonin transporter | Serotonin transporter inhibitor | INHIBITOR | https://conductscience.org/library/genes/6532 |
Source ChEMBL
Diseases60
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 60Source Open Targets
See all 60 diseasesTrials234
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 3 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01360866 | Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) | Phase 3 | 2,944 | 2018-09-17 | fluoxetine | Its name | ClinicalTrials.gov |
| NCT03466346 | SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project | 2,162 | 2025-12-02 | fluoxetine | Its name | ClinicalTrials.gov | |
| NCT00958568 | A Study in Relapse Prevention of Treatment-Resistant Depression | Phase 3 | 892 | 2014-04-01 | fluoxetine | Its name | ClinicalTrials.gov |
| NCT02709746 | Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD) | Phase 3 | 784 | 2020-08-19 | fluoxetine | Its name | ClinicalTrials.gov |
| NCT00666757 | A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression | Phase 4 | 750 | 2010-06-15 | fluoxetine | Its name | ClinicalTrials.gov |
| NCT04597190 | Sequenced Treatment Effectiveness for Posttraumatic Stress | Phase 4 | 700 | 2025-03-26 | fluoxetine | Its name | ClinicalTrials.gov |
| NCT02655354 | A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity | 635 | 2021-07-02 | fluoxetine | Its name | ClinicalTrials.gov | |
| NCT02431806 | Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder | Phase 3 | 552 | 2020-09-07 | fluoxetine | Its name | ClinicalTrials.gov |
| NCT00118404 | Cognitive Therapy for Recurrent Depression | Phase 3 | 523 | 2014-06-05 | fluoxetine | Its name | ClinicalTrials.gov |
| NCT01808612 | A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing | Phase 3 | 513 | 2015-05-12 | fluoxetine | Its name | ClinicalTrials.gov |
1 to 10 of 234
See all 234 trialsComparisons in its trials49
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Intervention vs Usual Care: deaths from any cause | 6 of 265 | 3 of 370 | 635 | NCT02655354 | Trial comparisons |
| Intervention vs Usual Care: serious adverse events | 15 of 265 | 13 of 370 | 635 | NCT02655354 | Trial comparisons |
| Family-aided Assertive Community Treatment vs Control Group: serious adverse events | 0 of 205 | 1 of 87 | 292 | NCT00531518 | Trial comparisons |
| Sequential Fluoxetine vs Sequential Placebo: Number of Participants Achieving Smoking Abstinence | 24 of 107 | 18 of 99 | 206 | NCT00578669 | Trial comparisons |
| Sequential Fluoxetine vs Sequential Placebo: deaths from any cause | 0 of 107 | 0 of 99 | 206 | NCT00578669 | Trial comparisons |
| Sequential Fluoxetine vs Sequential Placebo: serious adverse events | 0 of 107 | 0 of 99 | 206 | NCT00578669 | Trial comparisons |
| Olanzapine + Fluoxetine vs Placebo + Fluoxetine: serious adverse events | 1 of 88 | 1 of 87 | 175 | NCT01687478 | Trial comparisons |
| Continued Medication Alone vs Continued Medication Plus CBT: serious adverse events | 7 of 69 | 9 of 75 | 144 | NCT00612313 | Trial comparisons |
| Zolpidem-CR vs Placebo: deaths from any cause | 0 of 51 | 0 of 52 | 103 | NCT01689909 | Trial comparisons |
| Zolpidem-CR vs Placebo: serious adverse events | 1 of 51 | 0 of 52 | 103 | NCT01689909 | Trial comparisons |
1 to 10 of 49
See all 49 comparisons in its trialsPapers from its trials403
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials16
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Attention Network Test | 1 | 0 | ConductCognition |
| Ball-Toss Game | 1 | 0 | ConductCognition |
| Card Sorting Test (Berg) | 1 | 0 | ConductCognition |
| Continuous Performance Test | 1 | 0 | ConductCognition |
| Choice Reaction Time | 1 | 0 | ConductCognition |
| Go/No-Go Task | 1 | 0 | ConductCognition |
| 1-Back Task | 1 | 0 | ConductCognition |
| 2-Back Task | 1 | 0 | ConductCognition |
| Probabilistic Reversal Learning | 1 | 0 | ConductCognition |
| Psychomotor Vigilance Task | 1 | 0 | ConductCognition |
1 to 10 of 16
See all 16 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL41
GET https://conductscience.org/api/drugs/v1/CHEMBL41/diseases?page=2